NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $6.30 +0.23 (+3.79%) Closing price 04:00 PM EasternExtended Trading$6.31 +0.01 (+0.16%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CorMedix Stock (NASDAQ:CRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CorMedix alerts:Sign Up Key Stats Today's Range$5.88▼$6.3550-Day Range$6.07▼$12.4252-Week Range$3.61▼$13.85Volume1.18 million shsAverage Volume996,773 shsMarket Capitalization$410.65 millionP/E RatioN/ADividend YieldN/APrice Target$15.14Consensus RatingBuy Company OverviewCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More… Remove Ads CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCRMD MarketRank™: CorMedix scored higher than 53% of companies evaluated by MarketBeat, and ranked 523rd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CorMedix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.22% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in CorMedix has recently increased by 3.81%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.22% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in CorMedix has recently increased by 3.81%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.55 News SentimentCorMedix has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for CorMedix this week, compared to 3 articles on an average week.Search Interest18 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows8 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Stock News HeadlinesCorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 8:30 AM | globenewswire.comQ1 Earnings Forecast for CorMedix Issued By Leerink PartnrsMarch 30 at 1:15 AM | americanbankingnews.comDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.April 2, 2025 | Altimetry (Ad)CorMedix Inc. Reports Record Q4 Earnings and GrowthMarch 28, 2025 | tipranks.comCorMedix: A Fair-Priced Biotech Company With A Bright FutureMarch 28, 2025 | seekingalpha.comCORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the FirmMarch 27, 2025 | globenewswire.comCorMedix (NASDAQ:CRMD) Price Target Cut to $12.00 by Analysts at Needham & Company LLCMarch 27, 2025 | americanbankingnews.comThe Hidden Risks Behind CorMedix's First Profitable QuarterMarch 27, 2025 | seekingalpha.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $8.10 at the start of the year. Since then, CRMD stock has decreased by 23.2% and is now trading at $6.22. View the best growth stocks for 2025 here. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) announced its quarterly earnings results on Tuesday, March, 25th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.05. The company's revenue was up 29900.0% compared to the same quarter last year. When did CorMedix's stock split? Shares of CorMedix reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AUO (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR). Company Calendar Last Earnings3/25/2025Today4/02/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.14 High Stock Price Target$19.00 Low Stock Price Target$12.00 Potential Upside/Downside+149.5%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,340,000.00 Net MarginsN/A Pretax Margin-387.73% Return on Equity-79.21% Return on Assets-64.68% Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.60 Sales & Book Value Annual Sales$43.47 million Price / Sales9.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book4.74Miscellaneous Outstanding Shares65,182,000Free Float57,522,000Market Cap$395.65 million OptionableOptionable Beta1.53 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CRMD) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.